Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease, a multicenter, randomized, double-blind, placebo-controlled clinical trial

  • Bañares, Juan|||0000-0002-1966-1947
  • Aceituno, Laia|||0000-0001-5414-2408
  • Ruiz-Ortega, Lourdes|||0000-0003-3636-3367
  • Pons Delgado, Mònica|||0000-0002-0985-3320
  • Abraldes, Juan G.|||0000-0003-3421-937X
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Zinc homeostasis could play a role in compensated advanced chronic liver disease, and its supplementation has been linked to improvement in liver function, a decrease of hepatic complications, and reduction in HCC incidence. Compensated advanced chronic liver disease encompasses a heterogeneous group of patients with variable risks of clinically significant portal hypertension and clinical events. The ANTICIPATE model is a validated model for stratifying these risks. Our aim is to demonstrate that zinc administration can reduce the rate and risk of presenting clinical events (first decompensation, HCC, death, and liver transplantation). This study protocol describes an ongoing phase III, national, multicenter, randomized, double-blind clinical trial that will enroll 300 patients to receive either the trial treatment (zinc acexamate) or placebo. An inclusion period of 42 months is planned, with a minimum follow-up of 2 years. Our principal hypothesis is that zinc could modify the natural history of patients with compensated advanced chronic liver disease, with an overall improvement in prognosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease

  • Aceituno, Laia|||0000-0001-5414-2408
  • Bañares, Juan|||0000-0002-1966-1947
  • Pons Delgado, Mònica|||0000-0002-0985-3320
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Sabiote, Clara
  • Cammà, Calogero
  • Ciancimino, Giacinta
  • Pennisi, Grazia
  • Tulone, Adele
  • Ma, Mang M.
  • Liu, X.
  • Watkins, Timothy R.
  • Billin, Andrew N.
  • Petta, Salvatore
  • Pericàs, Juan M.|||0000-0002-3645-3293
  • Abraldes, Juan G.|||0000-0003-3421-937X
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Background & Aims: The reference for risk stratification and clinical trial selection of metabolic dysfunction-associated steatotic liver disease (MASLD) patients is fibrosis degree by histology. The noninvasive ANTICIPATE-NASH models have been validated for risk prediction of clinically significant portal hypertension (CSPH) and liver-related events (LRE). We assessed whether these models provide better risk stratification of events than histology. Methods: A multicenter cohort 1, including 699 biopsy specimen-proven F3-F4 patients with MASLD was evaluated. The end point was LRE (hepatic decompensation, hepatocellular carcinoma, transplantation, or liver-related death). We assessed (Cox regression) whether histology provided added value to ANTICIPATE-NASH and whether model predictions differed in F3/F4 patients. Results were validated in cohort 2 (1396 F3-F4 patients) from 4 clinical trials using the clinical regulatory end point. Results: In cohort 1, F3 and F4 were equally distributed. There were 56 LREs (8.0%) during follow-up, concentrated in F4 (51 LREs). The ANTICIPATE-NASH model showed excellent discrimination (C statistic, 0.93) for LRE, higher than histology (C statistic, 0.67). Model calibration was excellent. Adding histology did not improve model prediction. Thresholds of ANTICIPATE-NASH above which F3 patients developed LREs and below which F4 patients did not were identified. Results were reproduced in cohort 2 with the regulatory end point, with higher model discrimination (C statistic, 0.84) compared with histology (C statistic, 0.64). Conclusions: In MASLD patients with F3/F4, the noninvasive ANTICIPATE-NASH models provide better risk stratification of clinical events than histologic classification. These models could be very useful for clinical trials by selecting patients at risk of clinical events and patients with higher chances of observed cirrhosis regression.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Refining the Baveno VII criteria for clinically significant portal hypertension, An individual patient data meta-analysis

  • Bañares, Juan|||0000-0002-1966-1947
  • Pons, Monica
  • Reiberger, Thomas|||0000-0002-4590-3583
  • Mandorfer, Mattias|||0000-0003-2330-0017
  • Jachs, M.|||0000-0003-2871-4147
  • Semmler, Georg|||0000-0002-0411-166X
  • Colecchia, A.
  • Colecchia, L.|||0000-0002-0217-8780
  • Dajti, E.|||0000-0003-2905-1146
  • Bureau, C.|||0000-0001-8634-9278
  • Larrue, Helene|||0000-0003-3216-7692
  • Grgurević, I.|||0000-0003-0520-3483
  • Fortea, Jose Ignacio|||0000-0001-5255-9445
  • Puente, Angela
  • Berzigotti, A.
  • Tsochatzis, Emmanuel A.
  • Bosch, Jaime|||0000-0003-3414-0055
  • Abraldes, Juan G.|||0000-0003-3421-937X
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Background & Aims Clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD) has major therapeutic implications. CSPH can be assessed using the Baveno VII criteria, though performance is reduced in patients with obesity (BMI ≥30 kg/m) and metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to validate the Baveno VII criteria and refine them using the ANTICIPATE ± NASH models. Methods We conducted a systematic review of studies validating the Baveno VII criteria for diagnosing CSPH, using hepatic venous pressure gradient as the reference standard. A search combining "CSPH" AND "Baveno VII" was performed from the Baveno VII consensus publication until June 2024. A meta-analysis evaluated the rule-in criterion (liver stiffness measurement [LSM] ≥25 kPa) and rule-out criterion (LSM ≤15 kPa + platelet count ≥150 × 10/L). We also assessed whether applying a ≥90% positive predictive value (PPV) risk threshold for CSPH, as predicted by ANTICIPATE ± NASH, improved diagnostic performance. Individual patient data were analyzed to evaluate model performance by center. Results Five studies including 1,433 patients with cACLD (CSPH prevalence 34-62%) of various etiologies were identified. The rule-in threshold of LSM ≥25 kPa achieved an overall pooled PPV of 92% across etiologies, except in MASLD with obesity. Applying a ≥75% CSPH risk threshold from the ANTICIPATE ± NASH models increased the PPV to 95%, including among patients with MASLD and obesity (PPV improved from 0.67 to 0.83; p <0.001). The pooled negative predictive value for the rule-out criterion was 99% across all etiologies. ANTICIPATE ± NASH models performed consistently well across centers. Conclusion The Baveno VII criteria accurately classify CSPH across etiologies, except in MASLD with obesity. Incorporating a ≥75% risk threshold from the ANTICIPATE ± NASH models enhances diagnostic accuracy, particularly in MASLD with obesity, and may provide a simpler approach for identifying CSPH in clinical practice. Impact and implications This systematic review and meta-analysis confirm the validity of the Baveno VII criteria for both ruling out and ruling in clinically significant portal hypertension in patients with compensated advanced chronic liver disease. Applying a ≥75% risk threshold from the ANTICIPATE ± NASH models further improves overall diagnostic performance across etiologies. This provides a practical and accessible approach for hepatologists to identify candidates for prophylactic β-blocker therapy, as the calculation is based on simple clinical parameters - body mass index, liver stiffness, and platelet count - using an online calculator.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Proteomic Analysis of Dysfunctional Liver Sinusoidal Endothelial Cells Reveals Substantial Differences in Most Common Experimental Models of Chronic Liver Diseases

  • Gil Soler, Mar
  • Azkargorta, Mikel
  • Fuster Ruiz, Carla
  • Martínez Gómez, María
  • Raurell Saborit, Immaculada
  • Barberá Bellés, Aurora
  • Hide, Diana
  • Martell Pérez-Alcalde, Maria
  • Pericas, Juan M
  • Genesca, Joan
Animal models; Chronic liver disease; Endothelial dysfunction, Models animals; Malaltia hepàtica crònica; Disfunció endotelial, Modelos animales; Enfermedad hepática crónica; Disfunción endotelial, Molecular markers of dedifferentiation of dysfunctional liver sinusoidal endothelial cells (LSEC) have not been fully elucidated. We aimed at deciphering the molecular profile of dysfunctional LSEC in different pathological scenarios. Flow cytometry was used to sort CD11b−/CD32b+ and CD11b−/CD32b− LSEC from three rat models of liver disease (bile duct ligation-BDL; inhaled carbon tetrachloride-CCl4; and high fat glucose/fructose diet-HFGFD). A full proteomic profile was performed applying nano-scale liquid chromatography tandem mass spectrometry (nLC-MS) and analyzed with PEAKS software. The percentage of CD32b− LSEC varied across groups, suggesting different capillarization processes. Both CD32+ and CD32b− LSEC from models are different from control LSEC, but differently expressed proteins in CD32b− LSEC are significantly higher. Heatmaps evidenced specific protein expression patterns for each model. Analysis of biological significance comparing dysfunctional CD32b− LSEC with specialized CD32b+ LSEC from controls showed central similarities represented by 45 common down-regulated proteins involved in the suppression of the endocytic machinery and 63 common up-regulated proteins associated with the actin-dependent cytoskeleton reorganization. In summary; substantial differences but also similarities in dysfunctional LSEC from the three most common models of liver disease were found, supporting the idea that LSEC may harbor different protein expression profiles according to the etiology or disease stage., This work was supported by grants PI18/00947 and AC18/00033 (ENM3 2018) and PI21/00691 from Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union (ERDF/ESF, “Investing in your future”). J.G. is the recipient of a clinical intensification award and D.H. of a Sara Borrell grant, both from ISCIII. M.G. and A.B. have predoctoral fellowships from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) and ISCIII respectively. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is supported by ISCIII. The APC was funded by ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Review article: The need for more efficient and patient-oriented drug development pathways in NASH—setting the scene for platform trials

  • Di Prospero, Nicholas A.
  • Anstee, Quentin M.
  • Mesenbrinck, Peter
  • Kjær, Mette S
  • Rivera-Esteban, Jesús
  • Sena, Elena
  • Genesca, Joan
  • Pericas, Juan M
  • Manzano-Nunez, Ramiro
Drug development; Non-alcoholic steatohepatitis; Study designs, Desenvolupament de fàrmacs; Esteatohepatitis no alcohòlica; Dissenys d'estudi, Desarrollo de fármacos; Esteatohepatitis no alcohólica; Diseños de estudio, Background and Aims Non-alcoholic steatohepatitis (NASH) constitutes a significant unmet medical need with a burgeoning field of clinical research and drug development. Platform trials (PT) might help accelerate drug development while lowering overall costs and creating a more patient-centric environment. This review provides a comprehensive and nuanced assessment of the NASH clinical development landscape. Methods Narrative review and expert opinion with insight gained during the EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) project. Results Although NASH represents an opportunity to use adaptive trial designs, including master protocols for PT, there are barriers that might be encountered owing to distinct and sometimes opposing priorities held by these stakeholders and potential ways to overcome them. The following aspects are critical for the feasibility of a future PT in NASH: readiness of the drug pipeline, mainly from large drug companies, while there is not yet an FDA/EMA-approved treatment; the most suitable design (trial Phase and type of population, e.g., Phase 2b for non-cirrhotic NASH patients); the operational requirements such as the scope of the clinical network, the use of concurrent versus non-concurrent control arms, or the re-allocation of participants upon trial adaptations; the methodological appraisal (i.e. Bayesian vs. frequentist approach); patients' needs and patient-centred outcomes; main regulatory considerations and the funding and sustainability scenarios. Conclusions PT represent a promising avenue in NASH but there are a number of conundrums that need addressing. It is likely that before a global NASH PT becomes a reality, ‘proof-of-platform’ at a smaller scale needs to be provided., JMP reports having received consulting fees from Boehringer-Ingelheim, MSD and Novo Nordisk. He has received speaking fees from Gilead, Intercept, and Novo Nordisk, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Madrigal, Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD. Funds from European Commission/EFPIA IMI2 853966-2, IMI2 777377, H2020 847989, and ISCIII PI19/01898. NAdP works for Janssen. QMA is Coordinator of the EU IMI-2 LITMUS consortium, which is funded by the EU Horizon 2020 programme and EFPIA. This multistakeholder consortium includes industry partners. He reports research Grant Funding: Allergan/Tobira, AstraZeneca, Boehringer-Ingelheim, Glaxo SmithKline, Glympse Bio, Intercept, Novartis Pharma AG, Pfizer Ltd. Consultancy: 89Bio, Abbvie/Allergan, Akero, Altimentiv, Altimmune, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Boehringer-Ingelheim, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd., Galmed, Genentech, Genfit SA, Gilead, Grunthal, HistoIndex, Indalo, Intercept Pharma Europe Ltd., Inventiva, IQVIA, Janssen, Johnson & Johnson, Madrigal, MedImmune, Medpace, Merck, Metacrine, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, PathAI, Pfizer Ltd., Poxel, ProSciento, Raptor Pharma, Roche, Servier, Shionogi, Terns, The Medicines Company, Viking Therapeutics. Speaker: Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, Kenes, Medscape. Royalties: Elsevier Ltd. PM works for Novartis. MSK is an employee of and a shareholder in Novo Nordisk A/S. JG has received consulting fees from Boehringer-Ingelheim, speaking fees from Echosens and travel expenses from Gilead and Abbie. Funds from ISCIII PI18/00947 and PI21/00691. JRE has received speaking fees from Gilead. FT lab’ work has been supported by the German Research Foundation (DFG, CRC/TR 362) and research grants from Gilead, Allergan, Bristol-Myers Squibb and Inventiva. VR consults for and Intercept, Novo Nordisk, Galmed, Poxel, NGM, Madrigal, Enyo, Sagimet, 89 Bio, Prosciento, Terns, and Theratechnologies, and received grants from Intercept and Gilead.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report

  • Rivera Esteban, Jesus Manuel
  • Barbera Belles, Aurora
  • Salcedo Allende, Maria Teresa
  • Martell Pérez-Alcalde, María
  • Genescà Ferrer, Joan
  • Pericàs Pulido, Juan Manuel
Esteatosi hepàtica; Hipertensió portal, Liver steatosis; Portal hypertension, Esteatosis hepática; Hipertensión portal, No financial support was received for data analysis or writing assistance. JRE is a PhD student at Universitat Autònoma de Barcelona, Spain. JMP reports having received consulting fees from Boehringer Ingelheim, MSD and Novo Nordisk. He has received speaking fees from Gilead, Intercept, and Novo Nordisk, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Madrigal, Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD. Funds from European Commission/EFPIA IMI2 853966-2, IMI2 777377, H2020 847989, and ISCIII PI19/01898 (PI22/01770). JG has received consulting fees from Boehringer Ingelheim, speaking fees from Echosens and travel expenses from Gilead and Abbie. Funds from ISCIII PI18/00947 and PI21/00691. All other authors: nothing to disclose.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD, A proof of concept case report

Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Proteomic Analysis of Dysfunctional Liver Sinusoidal Endothelial Cells Reveals Substantial Differences in Most Common Experimental Models of Chronic Liver Diseases

  • Gil Soler, Mar
  • Azkargorta, Mikel
  • Fuster Ruiz, Carla
  • Martínez Gómez, María
  • Raurell Saborit, Immaculada
  • Barberá Bellés, Aurora
  • Hide, Diana
  • Martell Pérez-Alcalde, Maria
  • Pericas, Juan M
  • Genesca, Joan
Animal models; Chronic liver disease; Endothelial dysfunction, Models animals; Malaltia hepàtica crònica; Disfunció endotelial, Modelos animales; Enfermedad hepática crónica; Disfunción endotelial, Molecular markers of dedifferentiation of dysfunctional liver sinusoidal endothelial cells (LSEC) have not been fully elucidated. We aimed at deciphering the molecular profile of dysfunctional LSEC in different pathological scenarios. Flow cytometry was used to sort CD11b−/CD32b+ and CD11b−/CD32b− LSEC from three rat models of liver disease (bile duct ligation-BDL; inhaled carbon tetrachloride-CCl4; and high fat glucose/fructose diet-HFGFD). A full proteomic profile was performed applying nano-scale liquid chromatography tandem mass spectrometry (nLC-MS) and analyzed with PEAKS software. The percentage of CD32b− LSEC varied across groups, suggesting different capillarization processes. Both CD32+ and CD32b− LSEC from models are different from control LSEC, but differently expressed proteins in CD32b− LSEC are significantly higher. Heatmaps evidenced specific protein expression patterns for each model. Analysis of biological significance comparing dysfunctional CD32b− LSEC with specialized CD32b+ LSEC from controls showed central similarities represented by 45 common down-regulated proteins involved in the suppression of the endocytic machinery and 63 common up-regulated proteins associated with the actin-dependent cytoskeleton reorganization. In summary; substantial differences but also similarities in dysfunctional LSEC from the three most common models of liver disease were found, supporting the idea that LSEC may harbor different protein expression profiles according to the etiology or disease stage., This work was supported by grants PI18/00947 and AC18/00033 (ENM3 2018) and PI21/00691 from Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union (ERDF/ESF, “Investing in your future”). J.G. is the recipient of a clinical intensification award and D.H. of a Sara Borrell grant, both from ISCIII. M.G. and A.B. have predoctoral fellowships from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) and ISCIII respectively. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is supported by ISCIII. The APC was funded by ISCIII.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Review article: The need for more efficient and patient-oriented drug development pathways in NASH—setting the scene for platform trials

  • Di Prospero, Nicholas A.
  • Anstee, Quentin M.
  • Mesenbrinck, Peter
  • Kjær, Mette S
  • Rivera-Esteban, Jesús
  • Sena, Elena
  • Genesca, Joan
  • Pericas, Juan M
  • Manzano-Nunez, Ramiro
Drug development; Non-alcoholic steatohepatitis; Study designs, Desenvolupament de fàrmacs; Esteatohepatitis no alcohòlica; Dissenys d'estudi, Desarrollo de fármacos; Esteatohepatitis no alcohólica; Diseños de estudio, Background and Aims Non-alcoholic steatohepatitis (NASH) constitutes a significant unmet medical need with a burgeoning field of clinical research and drug development. Platform trials (PT) might help accelerate drug development while lowering overall costs and creating a more patient-centric environment. This review provides a comprehensive and nuanced assessment of the NASH clinical development landscape. Methods Narrative review and expert opinion with insight gained during the EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) project. Results Although NASH represents an opportunity to use adaptive trial designs, including master protocols for PT, there are barriers that might be encountered owing to distinct and sometimes opposing priorities held by these stakeholders and potential ways to overcome them. The following aspects are critical for the feasibility of a future PT in NASH: readiness of the drug pipeline, mainly from large drug companies, while there is not yet an FDA/EMA-approved treatment; the most suitable design (trial Phase and type of population, e.g., Phase 2b for non-cirrhotic NASH patients); the operational requirements such as the scope of the clinical network, the use of concurrent versus non-concurrent control arms, or the re-allocation of participants upon trial adaptations; the methodological appraisal (i.e. Bayesian vs. frequentist approach); patients' needs and patient-centred outcomes; main regulatory considerations and the funding and sustainability scenarios. Conclusions PT represent a promising avenue in NASH but there are a number of conundrums that need addressing. It is likely that before a global NASH PT becomes a reality, ‘proof-of-platform’ at a smaller scale needs to be provided., JMP reports having received consulting fees from Boehringer-Ingelheim, MSD and Novo Nordisk. He has received speaking fees from Gilead, Intercept, and Novo Nordisk, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Madrigal, Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD. Funds from European Commission/EFPIA IMI2 853966-2, IMI2 777377, H2020 847989, and ISCIII PI19/01898. NAdP works for Janssen. QMA is Coordinator of the EU IMI-2 LITMUS consortium, which is funded by the EU Horizon 2020 programme and EFPIA. This multistakeholder consortium includes industry partners. He reports research Grant Funding: Allergan/Tobira, AstraZeneca, Boehringer-Ingelheim, Glaxo SmithKline, Glympse Bio, Intercept, Novartis Pharma AG, Pfizer Ltd. Consultancy: 89Bio, Abbvie/Allergan, Akero, Altimentiv, Altimmune, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Boehringer-Ingelheim, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd., Galmed, Genentech, Genfit SA, Gilead, Grunthal, HistoIndex, Indalo, Intercept Pharma Europe Ltd., Inventiva, IQVIA, Janssen, Johnson & Johnson, Madrigal, MedImmune, Medpace, Merck, Metacrine, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, PathAI, Pfizer Ltd., Poxel, ProSciento, Raptor Pharma, Roche, Servier, Shionogi, Terns, The Medicines Company, Viking Therapeutics. Speaker: Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, Kenes, Medscape. Royalties: Elsevier Ltd. PM works for Novartis. MSK is an employee of and a shareholder in Novo Nordisk A/S. JG has received consulting fees from Boehringer-Ingelheim, speaking fees from Echosens and travel expenses from Gilead and Abbie. Funds from ISCIII PI18/00947 and PI21/00691. JRE has received speaking fees from Gilead. FT lab’ work has been supported by the German Research Foundation (DFG, CRC/TR 362) and research grants from Gilead, Allergan, Bristol-Myers Squibb and Inventiva. VR consults for and Intercept, Novo Nordisk, Galmed, Poxel, NGM, Madrigal, Enyo, Sagimet, 89 Bio, Prosciento, Terns, and Theratechnologies, and received grants from Intercept and Gilead.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report

  • Rivera Esteban, Jesus Manuel
  • Barbera Belles, Aurora
  • Salcedo Allende, Maria Teresa
  • Martell Pérez-Alcalde, María
  • Genescà Ferrer, Joan
  • Pericàs Pulido, Juan Manuel
Esteatosi hepàtica; Hipertensió portal, Liver steatosis; Portal hypertension, Esteatosis hepática; Hipertensión portal, No financial support was received for data analysis or writing assistance. JRE is a PhD student at Universitat Autònoma de Barcelona, Spain. JMP reports having received consulting fees from Boehringer Ingelheim, MSD and Novo Nordisk. He has received speaking fees from Gilead, Intercept, and Novo Nordisk, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Madrigal, Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD. Funds from European Commission/EFPIA IMI2 853966-2, IMI2 777377, H2020 847989, and ISCIII PI19/01898 (PI22/01770). JG has received consulting fees from Boehringer Ingelheim, speaking fees from Echosens and travel expenses from Gilead and Abbie. Funds from ISCIII PI18/00947 and PI21/00691. All other authors: nothing to disclose.